Skip to main content

Drug Interactions between ritonavir and Roxicodone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

oxyCODONE ritonavir

Applies to: Roxicodone (oxycodone) and ritonavir

MONITOR CLOSELY: Coadministration with ritonavir or lopinavir-ritonavir may significantly increase the plasma concentrations of oxycodone. The proposed mechanism is ritonavir inhibition of CYP450 3A4 and 2D6, the former of which is primarily responsible for the N-demethylation of oxycodone to noroxycodone and the latter of which is responsible for the metabolism of noroxycodone to noroxymorphone. Approximately 11% of oxycodone is also O-demethylated via CYP450 2D6 to oxymorphone, which is further metabolized to noroxymorphone by CYP450 3A4. Increased oxycodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In twelve healthy volunteers, coadministration of ritonavir (300 mg orally twice daily for 4 days) and oxycodone (10 mg orally one hour after the first dose of ritonavir on day 3) resulted in a 1.7-fold and a 3.0-fold increase in oxycodone peak plasma concentration (Cmax) and systemic exposure (AUC), respectively, compared to oxycodone administered with placebo. Coadministration of the same dose of oxycodone with lopinavir-ritonavir (400 mg-100 mg orally twice daily for 4 days) resulted in a 1.4-fold and a 2.6-fold increase in oxycodone Cmax and AUC, respectively. Both ritonavir and lopinavir-ritonavir prolonged the elimination half-life of oxycodone from 3.6 to approximately 5.5 hours, and reduced the AUC of the metabolites noroxycodone and noroxymorphone by over 50% and 75%, respectively. While ritonavir alone had no effect on oxymorphone, lopinavir-ritonavir increased noroxymorphone AUC by 2.7-fold. These pharmacokinetic changes were accompanied by enhanced self-reported oxycodone effects.

MANAGEMENT: Pharmacologic response to oxycodone should be closely monitored during coadministration with ritonavir or lopinavir-ritonavir, and dosage adjustments made accordingly if necessary. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur such as dizziness, confusion, fainting, extreme sedation, bradycardia, slow or difficult breathing, and shortness of breath.

References

  1. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD (2004) "Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes." Drug Metab Dispos, 32, p. 447-54
  2. Nieminen TH, Hagelberg NM, Saari TI, et al. (2010) "Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir." Eur J Clin Pharmacol, 66, p. 977-85

Switch to consumer interaction data

Drug and food interactions

Major

oxyCODONE food

Applies to: Roxicodone (oxycodone)

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including oxycodone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of oxycodone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of oxycodone by certain compounds present in grapefruit, resulting in decreased formation of metabolites noroxycodone and noroxymorphone and increased formation of oxymorphone due to a presumed shifting of oxycodone metabolism towards the CYP450 2D6-mediated route. In 12 healthy, nonsmoking volunteers, administration of a single 10 mg oral dose of oxycodone hydrochloride on day 4 of a grapefruit juice treatment phase (200 mL three times a day for 5 days) increased mean oxycodone peak plasma concentration (Cmax), systemic exposure (AUC) and half-life by 48%, 67% and 17% (from 3.5 to 4.1 hours), respectively, compared to administration during an equivalent water treatment phase. Grapefruit juice also decreased the metabolite-to-parent AUC ratio of noroxycodone by 44% and that of noroxymorphone by 45%. In addition, oxymorphone Cmax and AUC increased by 32% and 56%, but the metabolite-to-parent AUC ratio remained unchanged. Pharmacodynamic changes were modest and only self-reported performance was significantly impaired after grapefruit juice. Analgesic effects were not affected.

MANAGEMENT: Patients should not consume alcoholic beverages or use drug products that contain alcohol during treatment with oxycodone. Any history of alcohol or illicit drug use should be considered when prescribing oxycodone, and therapy initiated at a lower dosage if necessary. Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension. Due to a high degree of interpatient variability with respect to grapefruit juice interactions, patients treated with oxycodone may also want to avoid or limit the consumption of grapefruit and grapefruit juice.

References

  1. Nieminen TH, Hagelberg NM, Saari TI, et al. (2010) "Grapefruit juice enhances the exposure to oral oxycodone." Basic Clin Pharmacol Toxicol, 107, p. 782-8

Switch to consumer interaction data

Moderate

ritonavir food

Applies to: ritonavir

ADJUST DOSING INTERVAL: Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.

MANAGEMENT: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.

References

  1. (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.